Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6548155 | 1.00 | L3MBTL1 (0.37) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6549217 | 0.97 | L3MBTL1 (0.38) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6549222 | 0.97 | L3MBTL1 (0.38) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6547759 | 0.94 | L3MBTL1 (0.36) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6547756 | 0.94 | L3MBTL1 (0.36) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6548187 | 0.93 | MEN1 (0.35) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6548190 | 0.93 | MEN1 (0.35) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6549257 | 0.91 | PPARG (0.39) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6549261 | 0.91 | PPARG (0.39) | L3MBTL1MEN1KMT2AMAPTTDP1 | |
| SCHEMBL6548569 | 0.91 | SRC (0.33) | L3MBTL1MEN1KMT2AMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975586-B1 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6448444-B2 | INSECTICIDES, MITICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6437184-B1 | INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | CBR3, CBR1, NOX3 | L3MBTL1 876/4885MEN1 4425/4885KMT2A 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.